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B 4.3 Endovascular Procedures for Intermittent Claudication
B 4.3.1 General Concepts Regarding Catheter Intervention in PAD
Intervention by endovascular procedure or surgery is only indicated in selected patients with IC
in whom exercise treatment has failed. Imaging-guided catheter intervention for PAD was first
described by Dotter and [udkins- in 1964. Since that original report of PTA in femoropopliteal
arteries using coaxial catheter techniques, more than 30 years have passed. The materials and
methods have now been refined, practitioners have been and continue to be trained, and the
application of percutaneous transluminal balloon angioplasty (PTA) and now stenting in PAD
has become more widespread.
Endovascular interventions other than balloon and stent procedures may have a limited applica-
tion in selected patients and are therefore not emphasized here. The following section considers
the role of PTA and stenting in PAD patients with IC and aortoiliac disease, femoropopliteal
disease, or both. Most trials cited were on claudicants only. Thrombolytic therapy has a role in
some new claudicants and in previously stable claudicants whose symptoms worsen because of
thrombosis superimposed on atherosclerotic stenosis (particularly those with thrombus-domi-
nant rather than plaque-dominant occlusions). However, the topic of thrombolytic therapy in
PAD has been treated in another consensus document and will be discussed in Acute and
Critical Limb Ischemia (sections C and D).2
Although the degree of disability is obviously a prime consideration, anticipated short- and
long-term clinical benefit is the major determinant of the role of catheter techniques in the
management of claudication. Metallic stents are surely the latest major technical/methodologi-
cal development to impact endovascular treatment of PAD, and stented endografts may soon
follow. However, to appreciate their currently understood role in the treatment of patients with
IC, it is first necessary to know the indications and results of PTA above and below the inguinal
ligament and their relationship to lesion characterization. It is also necessary to appreciate the
problems and limitations of both the disease/treatment and the evidence in the literature.
The issue of the preferred interventional technique tor particular types of lesions needs to be
addressed. However, it is difficult to be categorical about such recommendations, because the
management of an individual lesion in a particular patient depends on a large number of factors.
Management will vary according to local circumstances. Furthermore, with the rapid develop-
ment of new interventional techniques, the optimal treatment for a particular patient willvary
not only from place to place but also within the same institution as new expertise is developed.
It has therefore been decided to define types of lesions for interventions and then place
them in four groups, each group usually being treated in a similar way. The two extremes
are type A lesions, in which endovascular approach is the treatment of choice, and type D
lesions, in which surgery is the treatment of choice. Between these two groups are types B
and C lesions, in which no firm recommendations can be made about the preferred inter-
ventional option. At present, endovascular treatment is more commonly used in type B
lesions, and surgical treatment is more commonly used in type C lesions. It should be
emphasized that there is insufficient solid evidence to make any firm recommendations,
particularly in the case of types Band C. This proposed classification of types of lesions
may have the advantage of encouraging the standardization of description of lesions and
promoting the reporting of results in such a way that in the future it will be possible to
make firmer recommendations about the optimal treatment for particular types of lesion.
This system of presentation is used throughout the document to categorize types of
lesions and their preferred treatment. This system was devised in a similar structure to the
AHA classification, but differs significantly in content.
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B 4.3.2 Aortoiliac PTA
PTA is generally applied to more focal disease, for instance, of the distal abdominal aorta, com-
mon iliac arteries, and external iliac arteries. For diffuse, extensive, complex, multilevel, multifo-
cal, or totally occluded atherosclerotic segments of the infrarenal abdominal aorta and iliac
arteries, the procedure of choice is surgery.
Recommendation 31: Morphological stratification of iliac lesions
TASC type A iliac lesions:
1. Single stenosis <3 cm of the CIA or EIA (unilateral/bilateral)
TASC type B iliac lesions:
2. Single stenosis 3-10 cm in length, not extending into the common femoral artery
(CFA)
3. Total of two stenosis <5 em long in the CIA and/or EIA and not extending into
the CFA
4. Unilateral CIA occlusion
TASC type C iliac lesions:
5. Bilateral 5-10-cm-Iong stenosis of the CIA and/or EIA, not extending into the
CFA
6. Unilateral EIA occlusion not extending into the CFA
7. Unilateral EIA stenosis extending into the CFA
8. Bilateral CIA occlusion
TASC type D iliac lesions:
9. Diffuse, multiple unilateral stenoses involving the CIA, EIA, and CFA (usually
>10 em)
10. Unilateral occlusion involving both the CIA and EIA
11. Bilateral EIA occlusions
12. Diffuse disease involving the aorta and both iliac arteries
13. Iliac stenoses in a patient with an abdominal aortie aneurysm or other lesion
requiring aortic or iliac surgery
Abbreviations: CIA, common iliac artery; EIA, external iliac artery; CFA, common
femoral artery.
Recommendation 32: Treatment of choice for TASC type A and D aortoiliac lesions
Endovascular procedure is the treatment of choice for type A lesions, and surgery is the
procedure of choice for type D lesions.
Critical Issue 10: Treatment of TASC type B and C lesions
More evidence is needed to make any firm recommendations about the best treatment
for type B and C lesions. *
*CIRSE dissenting opinion:
Currently eudovascular treatment is more commonlyused[01' type B and C lesions, but more evidence is needed to make
any firm recommentiatioins nbou: besttretttment.
Reason [01' dissentinffopinion: Due to technicaldevelopments, t),pe C lesions of iliac anti femoral arteries can be treated by
endovascular means with a resonable technicalsuccess rate (for references, see B 4.3).
Therefore, CIRSE believes that in clinical practice these lesions are more commonly treated b)'endovtisculnr techniques,
althall!fh scientific evidenceof an)'superiority Oller vascular SIlrgery is lacking.
The technical and initial clinical success of PTA of iliac stenoses (Figure 21) in all series exceeds
90% and for focal iliac stenosis approaches 100%, The technical success rate of recanalization of
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Figure 21: Summary of preferred options in interventional management of iliac lesions.
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Surgical treatment of choice
segmental (external or common) iliac occlusions is 80% to 85% with or without additional fibri-
nolysis. Only a few studies have carefully documented clinical results over a long period of fol-
low-up using standard life-table methods and more exclusively in claudicants. These are listed in
Tables 17 and 18. Long-term patency rates in patients with Ie are close to 80% at 1 year and
60% at 5 years (Table 17, Table 18).3,4,5,6,7,8,9,10 Once an iliac artery occlusion has been
recanalized successfully, the patency rate docs not differ from that for patencies after PTA of
stenoses. However, complications are higher after recanalization of occlusions (6.0%) than after
standard PTA of stenoses (3.6%). Factors affecting patency have been identified (see A 3.2.9,
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Table 17: Patency rates for PTA of iliac artery stenoses (patency based on ABPI)
Claud- Technical
Patimts Study icants success Primary patency rate (%)* Complic-
(limbs) design (%) (%) 1y 3y 5y arion (%)t Comments
Tegtmeyer er al,3 1991 200 (263) R 59 93 92 82 78 4.4 85% 5yr secondary
patency
Jeans er a1,4- 1990 180(243) P 73 88 67 60 57 62% 5yr primary
patency in claudicants
Jorgensen et al,5 1992 150 (174) R 71 93 79t 68:1: 63t 2.3 81 % Syr secondary
patency
Johnston," 1993 (584) R 91 99 77 61 54 3.6 68% 3yr erA patency
51% 3yr ErA patency
Weightedm'emge (/,264) 77 95 78 66 61 3.6
Abbreviations: R, retrospective; P, prospective.
*Including technical failures.
tlncluding major or 'significant' complications, as tar as distinguished in the text.
fAdjusted for inclusion of technical failures.
Modified from Bosch JL, Hunink MGM.18
Table 18: Patency rates for PTA of iliac artery occlusions (patency based on ABPI)
Claud- Technical
Patients Stlldy icants success Primary patency rate (%) * Complic-
(limbs) design (%) (%) 1y 3y 5y ation (%Jt Comments
Colapinto et al,? 1985 (64) R 88 78 68:1: 61t 3.1 flup by ABPI
Hausegger et ai,S 1991 42 (42) R 81 83 67 5 fjup by AErI; addi-
tional fibrinolysis in
36 patients; secondary
stenr placement in
16 patients
[ohnsron,« 1993 (82) R 91 82 60 48 4.8 59% 3-year patency
excluding rccanaliza-
tion failures; 66% 3-
year success rate after
Cox regression estimate
Blum et al,? 1993 47 (47) P 64 98 94:1: 85t 10.6 f/up by Duplex; fib-
rinolysis in all cases;
secondary srcnts in
18 patients
Gupta er al,10 1993 50 (56) R 77 79 59t 56t 56t 8.0 f/up by ABPI; 61%
3-year secondary
patency
WeightedlI.l1emg e (291) 82 83 68 60 6.0
Study design: R- retrospective. P=prospective. f/up=follow-up.
"Including technical failures.
tlncluding major or 'significant' complications, as far as distinguished from the text.
t Adjusted for inclusion of technical failures.
Patency, p 542). Better results can be expected in common versus. external iliac stenoses, short
segmental versus long diffuse stenoses, patients with good versus poor runoff, and patients with
Ie versus limb salvage patients.
The use of PTA in the aortoiliac segment produces better results than when used in the
femoropopliteal region. In an. analysis of long-term results in the literature, Rutherford and
Durham-! produced composite patency curves for iliac and femoropopliteal PTA.
Femoropopliteal PTA had twice the initial and early (I-year) failure rate (16% vs 8% and 20%
per year vs 10% per year, respectively) but shared the same late failure rate (3%/y) as iliac PTA.
The 5-year patencies were 52% and 70%, respectively. Becker et al12 found a similar 5-year
patency rate (72%) in an analysis of 2,697 cases from the literature, noting that this was 79% in
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claudicants, Patency rates at 3 years are approximately 80% when performed for stenosis of the
iliac artery and 60% when performed for occlusion. An approximately 20% difference also is
found between common iliac and external iliac stenoses. Thus, it is clear that lesion location and
morphology greatly affect PTA results and that me selective application of PTA for claudicants
should be aimed at "favorable" lesions. Selective stenting may improve these results, but the use
of stenting to extend PTA to more extensive (less favorable) lesions has not been proved to be
more efficacious and is more costly (see also B 4.3, Endovascular Procedures, p 597).1 3,14
Table 19: Stcnts in iliac arteries-stenoses
CIaIId- Technical
Patients Study icants success Primary patCllcy rate (%)' Complic-
(limbs) design (%) (%) 1y 3y 5y arion (%Jt Comments
Palmaz er al,18 1992 486 (567) P 68 99 91 69 6.4 patency rate based on
clinical stage
Strecker et al,19 1993 116 (116) R 66 100 95 95 f/lip based on ABPI
Wolf et al,20 1993 37 (56) R 86 100 94 10.8 f/lip based on ABPI
Long er al,21 1995 61 (64) P 91 97 84 41 3.3 f/lip based on
Duplex
Henry er al,22 1995 184 (184) P 93 99 94 86 1.0 f/up by Duplex;
major complications
from both iliac and
fernpop stents; 94%
3yr secondary patency
5E3%
Martin ct al,23 1995 (163) P 77 97 81 4.3
Vorwerk ct al,24 199628 109 (118) R 97 100 97 86 72 3.4 tjup by Duplex
and/or D5A; 91% 3yr
secondary patency
5E3%
Murphy er al,29 66 (99) 52 91 78 53 7.6
Tetterooer al, 21 1998 143( 149) P 100 99 89 0 f/up by Duplex; parr
of randomized study
Weighted fII'cmgc 1,365 (1,430) 78 99 90 74 72 6.3
Abbreviations: R, retrospective; P, prospective; f/up,follow-up.
'Including technical failures,
tIncluding major or 'significant' complications, as far as can be distinguished from the text.
Modified from Bosch JL, Hunink MGM.18
Table 20: Stents in iliac arteries-occlusions
Claud- Technical
n Study icnnts success Primary patencyrate (%)' Complie-
(limbs) desW11 (%) (%) 1.1' 3y 5y tuion (%)t Comments
Hauscgger cr al,8 1991 16 (16) P 81 94 94 5 F/up based on ABP!
Blum et al,9 1993 18 (18) P 64 98 89 78 10.6 F/up based on
Duplex; primary
fibrinolysis
Vorwerk er al,II 1995 127 (127) R 91 80 68:1: 62:1: 35:1: 5.8 F/lip based on duplex
or D5A; 69% 3-year
secondary patency;
3%SE
Weighted al'cmge 187 86 82 72 64 5.6
NOTE. Study design: R, retrospective; P, prospective.
'Including technical failures.
t Including major or 'significant' complications as tar as can be distinguished from the text.
:j: Adjusted for inclusion of technical failures
B 4.3.3 Aortoiliac Stents
The availability of srenrs for use in aortoiliac PTA has improved the immediate hemodynamic
results of iliac PTA and effectively managed recoil and PTA-related flow-limiting dissections
(Table 19). Another application of iliac stenting is for treatment of chronic iliac artery occlu-
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sions. PTA alone often fails in cases of iliac occlusion because of dissection and marked elastic
recoil with re-obstruction of the lumen and a residual pressure gradient. Thus, before 1989, the
available literature was more critical to the use of PTA for iliac artery occlusions. This has
changed since large series have demonstrated a I-year and 3-years patency rate after successful
recanalization of90% and 80%, respectively (Table 20).8,9,15
Thus, the indications for iliac artery stenting, which are generally accepted in clinical practice,
are as follows:
• Insufficient hemodynamic result of PTA due to elastic recoil based on residual pressure gradient
• Massive, lumen-obstructing dissection
• Treatment of chronic occlusions
• Iliac artery ulceration associated with symptoms
• Restenoses after previously performed PTA
• Complex lesions for which primary stenting may give more satisfactory results
The value of hemodynamic measurements in addition to angiography to assess the result of PTA
and stent placement has been accepted. However, resting mean and systolic pressure gradients
were used as well as pressure gradients after vasodilatation. Objective thresholds of pressure gra-
dients for a hemodynamic significant stenosis do not exist. However, a resting mean pressure
gradient of more than 5 to 7 mm Hg and a posrvasodilatation mean pressure gradient of more
than 10 to 15 mm Hg are thresholds commonly used to define a hemodynamically significant
lesionlv (see Critical Issue 32, p 5208). However, more recent data have shown that iliac artery
stenting probably provides a more durable result than PTA alone for both stenoses and occlu-
sions on an intention-to-treat basis. One obvious reason is that stenting provides a better early
"result, which raises the starting point of the life-table curve. 17
Critical Issue 11: Use of pressure gradients to assess hemodynamic significance of
stenoses
Pressure gradient criteria with or without vasodilators for assessing hemodynamic sig-
nificance in iliac lesions remain to be established.
Critical Issue 12: Multiple stents
The usefulness and cost-effectiveness of multiple stents have yet to be established.
A recent meta-analysis by Bosch and Huninklf comparing the results of aortoiliac PTA versus.
aortoiliac stenting used a Medlars search of the post-1989 literature and yielded only six articles
(including 2,116 patients) with sufficient detail to allow stratification over subgroups with vari-
ous risk levels for long-term patency. Technical success was higher for stenting, whereas compli-
cation rates and 30-day mortality rates did not differ significantly. In patients with intermittent
claudication, the severity-adjusted 4-year primary patency rates (±95% confidence intervals) after
excluding technical failures, for PTA and stenting, were: 68% (65%-71 %) and 77% (72%-81 %),
respectively. Including technical failures, the 4-year primary patency rates are 65% (PTA) versus
77% (stem) for stenosis and 54% (PTA) versus 61% (stent) for occlusion. The relative risk of
long-term failure was reduced by 39% after stent placement compared with PTA.
In a re-analysis of the Palmaz multicenter iliac data, Laborde et all 9 determined the influence of
anatomic distribution of atherosclerosis (ie, disease severity) on the outcome of revascularization
by stenting. They divided the 455 patients of the study population into three groups accord.ing
to the Brewster classification of disease parterns-v and then used a statistical analysis to deter-
mine differences in outcome between groups. Brewster pattern type I includes only those
patients with focal aortoiliac disease or common iliac disease (39.6% of the study group);
Brewster pattern type II includes external iliac artery lesions (12.8% of the study group);
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Brewster pattern type III or multilevel disease involving the infrainguinal vessels was seen in
47.7% of study patients. "Complete relief of symptoms" occurred in 88.3% and 85.4% of
Brewster pattern type I and II patients, respectively, whereas only 60.1% of those with Brewster
pattern type III experienced complete relief (p " 0.05). Persistent clinical benefit at 36 months
was seen in 91.6% and 97.9% of patients with Brewster pattern type I and type II disease,
respectively, as compared with 60.8% in type III (p ... 0.006 for type II vs type III and p = 0.001
for type I vs type III, Wilcoxon test). Multivariate logistic regression showed that pattern type
III was the most powerful indicator of unsatisfactory early outcome in iliac stenting (p " 0.001).
Female gender also predicted unsatisfactory clinical outcome (p < 0.01) and higher periproce-
dural complications (p < 0.001).
The Dutch Iliac Stent Trial compared primary stent placement versus primary angioplasty fol-
lowed by selective stent placement in patients with claudication caused by iliac-artery obstructive
disease)? In the PTA group, selective stent placement was performed in 59 of 136 (43%) with a
residual mean pressure gradient greater than 10 mm Hg after balloon angioplasty. A primary
technical success was achieved in 279 of 286 patients (97.5%). A hemodynamic success was
achieved in 97% of the successfully recanalized iliac arteries. At 2 years, the clinical success rates
were 78% versus 76%, the hemodynamic success rates as assessed by ABPI measurements were
85% versus 85%, and the patency rates as measured by color Duplex were 71% versus 70% in the
stent versus PTA plus stent groups, respectively.
It should, however, be remembered that most patients in this study had IC with mild lesions,
and the results cannot be extrapolated to patients with more severe lesions. Thus, selective
stenting yields equivalent effectiveness and is less costly than primary stenting in the treatment
of claudication due to iliac artery stenoses.l 8,21 Furthermore, selective stenting compared with
PTA alone yields an increase in effectiveness that justifies the additional costs in these cases. (see
Table 19).22,23,24,25,26,27,28,29
To summarize, stents have influenced modern aortoiliac PTA by providing a means to oppose
elastic recoil, treat PTA-related dissections, and improve the long-term clinical results. In addi-
tion to these benefits, stents have provided a method to effectively treat TASC types C and D
aortoiliac bifurcation disease in selected patients. The short- and long-term clinical benefits of
iliac stenting are influenced by anatomic distribution of disease. Benefit is less variable and com-
plications and mortality are higher in patients with Brewster type III diseases than in those with
Brewster types I and II.
Recommendation 33: Role Qfstenting fur residual pressure gradient;, dissection, or elastic
recoil
Stenting Improves the technical and initial clinical success in cases of residual pressure
gradient or dissection after angioplasty, or in cases of elastic recoil.
Critical Issue 13: RQle of primary stenting of iliac occlusions
Primary stenting is widely used to optimize procedural results in iliac artery occlusions,
This practice needs to be subjected to rigorous clinical evaluation,
B 4.3.4 Femoropopliteal PTA
Selected PAD patients with claudication may be considered for femoropopliteal PTA. There are,
however, additional considerations. Patients with isolated aortoiliac disease tend to be younger
and have a low likelihood of coronary heart disease cornorbidity, whereas those with
femoropopliteal disease, infragenicular disease, or multilevel disease tend to have the lowest
ABPI and the highest likelihood of coronary heart disease comorbidity.30,31,32,33,34,35,36
Preservation of the saphenous veins for coronary bypass grafting is a potential advantage in such
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Recommendation 34: Morphological stratification of femoropopliteal lesions
TASC type A iliac lesions:
1. Single stenosis <3 em of the CIA or EIA (unilateral/bilateral)
TASC type B iliac lesions:
2. Single stenosis 3-10 em in length, not involving the distal popliteal artery*
3. Heavily calcified stenoses up to 3 em in length
4. Multiple lesions, each less than 3 cm (stenoses or occlusions)
5. Single or multiple lesions in the absence of continuous tibial runoff to improve
inflow for distal surgical bypass
TASC type C femoropopliteal lesions:
6. Single stenosis or occlusion longer than 5 em *
7. Multiple stenoses or occlusions, each 3-5 em, with or without heavy calcification
TASC type D femoropopliteal lesions:
8. Complete common femoral artery or superficial femoral artery occlusions or com-
plete popliteal and proximal trifurcation occlusions.
*CIRSE agrees except for thefollowing charlges:
Type Bfemoropoplitcal lesions:
2. Single stenosis or occlusions 3-10 em long) not im)oIOl,ing the distal poplitealartery
Type C[emoropopliteal lesions:
6. Single stenosis or oclusion >10 cm long
Reason fordissentillB opinion: TIJe lowerlong-term clinical success rate of long stenoses and occlusions in earlierstudies 1JJaS
due to a loll' technicalrate. However, developments of catheters and wiresha» improvedthe technicalSltCCeSS rate, to befol-
lowed byhigherpatencyrates.35,36 StutliescompMing PTA with bypass stilE":'!' in femorcpopliteal lesions 4-10 cm long do
not exist.
Recommendation 35: Treatment of choice for TASC type A and D femoropopliteallesions
Endovascular procedure is the treatment of choice for type A lesions, and surgery is the
procedure of choice for type D lesions.
Critical Issue 14: Treatment of TASC type B and C femoropopliteal Issions
More evidence is needed to make and firm recommendations about the best treatment
for types Band C lesions.
patients, in whom the benefit/risk ratios of surgery, PTA, and conservative therapy must be
weighed. Some high-risk patients may be offered PTA for their claudication; however, for such
patients, for example, those with diabetes mellitus, surgical bypass is usually reserved for severe
leg ischemia. As with aortoiliac disease, femoropopliteal lesions have been categorized in mor-
phological terms, with preferred therapeutic options as follows:
Several important studies of femoropopliteal PTA have appeared in the literature in recent years
(Figure 22).4,37,38,39,40 The primary success rates and the long-term patency rates of the suc-
cessfully dilated arteries are listed in Table 21. In only one study were all patients claudicants.
Table 22 shows estimated patency by length of lesion. These results are also discussed in Critical
Limb Ischemia (D 4.9, Infrainguinal Disease-Endovascular Treatment, p 5226).
Factors predicting outcome of PTA were evaluated in three studies37,38,39 using a Cox stepwise
multiple regression model. Factors predictive for a favorable outcome are claudication as an
indication, nondiabetic patients, proximally located short lesions, stenoses, good distal run-off,
and lack of a residual stenosis on the post-PTA angiogram, However, it also has been claimed
that once an occlusion has been recanalized, the long-term patency does not differ in compari-
son with srenoses.l? The technical success rate in stenoses is greater than 90%; in occlusions,
80% to 85%.
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Table 21: PTA of fernoropopliteal arteries-stenoses and occlusions
Claud- Technical
Patients Study icants success Primary patencyrate (%). Complic-
(limbs) desig11 (%) (%) 1y 3y 5y ation (%)f Comments
Gallino et al,41 1984 280 (329) R 61 87 62t 60t 58t 2.5 Flup based on
ABPI; 74% 2-y
primary patency in
stenoses, <3 em
occlusions in c1audicants
Krepel eral,42 1985 129 (164) R 90 84 68~ 5n 5n 6.0 38by coaxial Dotter
set; 88% technical
success in 126 balloon
cases
Jeans et al,4 1990 190 (190) P 51 82 50 45 41 F/up based onABPlj
5-y patencies- 61%
(stenoses) 31% (occlusions)
Capek et al, 37 1991 152 (217) R 74 90 71+ 51+ 48:): 5.5 Flup based onABPI
Johnston,38 1992 236 (254) R 80 96 63 51 38 6.3 Flup based on ABPI;
stcnosesy'occlusions
£10cm
Hurunk et al,43 1993 106(131) P 58 95 57 45 45 2.4 FILIp based onABPlj
55% 5-y patency for
stenoses-occlusions
Matsi et al,39 1994 106 (140) P 100 89 47 42 4.0 FILIp based on ABPI;
59% 3-y secondary
patency
Murray et al,40 1995 42 (44) P 89 93 86 53 5.0 Flup based on duplex;
>lO-cm lesions only;
24-mo patency, SE 26%
Weighted average 1,241 (1,469) 72 90 61 51 48 4.3
Abbreviations: R, retrospective; P, prospective.
*Induding technical failures.
t1ncluding major or "significant" complications, as far as Can be distinguished from the text.
tAdjusted for inclusion of technical failures.
The studies listed in Table 21 illustrate several interesting findings on the issue of transluminal
treatment of stenoses versus occlusions. Studies approximately 15 years old, such as those of
Gallino et al41 and Krepel et al,42 tended to show a greater impact of occlusion length on initial
technical success rates (33% and 26%, respectively, for occlusions larger than 3 cm) compared
with more recent studies. For example, in Matsi's 1994 study, the technical success for occlu-
sions 2 to 15cm in length was 83%. This compared to 91% for 125 stenoses.J? In Murray er
al's40 study, the authors remarked that earlier results of angioplasry bore little relevance to the
results that could now be achieved. Once a lesion is crossed and dilated, it has the same antici-
pated long-term success as a stenosis treated by PTA,37 Therefore, the principal reason that clin-
ical success rates reported in the past were lower for PTA of femoropopliteal occlusions than for
stenoses is that with lower initial technical successes the curves for occlusion started off lower.
The life-table patency and cumulative clinical success curves are, in fact, essentiallyparallel.
Iohnston's-f report seems to show dramatically better results for PTA offemoropopliteal
stenoses than occlusions. However, this was a re-analysis of an old PTA series and was therefore
subject to the same problems and limitations mentioned previously for older PTA series. The
most important factor that emerged from Johnston's study, as well as others, is that patients
with poor (0- to I-vessel) runoff consistently show poorer long-term outcomes than those with
2-3-vessel runoff. 38, 39,40,41,42 A summary of these observations is that (1) older
femoropopliteal PTA studies describe lower technical success with femoropopliteal occlusion
than do newer studies; (2) because of arbitrary limits placed on the transluminal technique and
imposed on a generation of interventionists, long-segment occlusions have not commonly been
attempted; (3) in the older literature, the apparently lower long-term clinical success of PTA for
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Figure 22: Summary of preferred options for intervcntional treatment of femoropopliteal lesions,
For detaUasee recommendation 33 and accompanying text
Note not allle.lona described In recommendation are Illustrated
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femoropopliteal occlusions compared with stenoses was attributable in large part to lower tech-
nical success (lesion crossing) and a resultant lower starting point on an otherwise identical life-
table curve (lower, but parallel); (4) by far the most consistent, important determinant of long-
term clinical success versus failure among the studies listed in Table 21 is not occlusion versus
stenosis at all, but rather the status of the runoff circulation below the knee.
An important study in this area is a decision and cost -effectiveness analysis of revascularization
procedures for femoropopliteal disease by Hunink et al (Table 23 ; Figure 23 ).45 The authors
used a literature review of mortality, morbidity, patency, and cost data as a source. They includ-
ed only procedures performed after 1985 . There were 4,800 PTA and 4,511 bypass operations.
They developed a decision analytic model to examine the choice between bypass surgery and
PTA for lesions amenable to either procedure. These patencies were offered to guide initial
strategy in patients with disabling claudication and femoropopliteal lesions .
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Table 22: Estimated patency by length of lesion
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R eference
Jeans er al,4 1990
Krepel ct al,38 1985
Krepel et al38 1985
Gallino et al,37 1984
Currie et al,44 1994
Murray ec al ,36 1995
Lengthof lesion
<l COl
<2 em
<3 em
<3 em
<5 COl
<7 em
Patency (%)
Stenoses @5 y;
<1 em = 76
> I em - 50; p < 0.05
longest lesion length implied
> 5 COl primary patency
stenoses @5 y;
<2 em = 77
>2 em = 54
longest lesion length not
stated primary vs secondary
patency not stated
occlusions @l y;
<3 em = 93
>3 em - 50
longest lesion length not
stated primary vs secondary
patency not stated
@2 )'; stenoses/ occlusions
< 3 em with 2-3 vessel run -
off - 71 occlusions with 0-1
vessel run-off = 37
@6mo;
<5 em = 59
>5 em = 4
stenoses @ 6 mo;
<7 COl = 81
>7 em - 23
longest lesion length not stated,
implied> 10 em .
Secondary patency but <5%
redilated
Inclusionoftechnical fm'lures
technical failures
included in life table
technical failures
excluded from results
technical failures
excluded from results
primary paten cy
technical failures
excluded from results
immediate failures
excluded
Indication
e LI with ABPI <0.5
90% claudication
90% claudication
claudication + Cl.I
eLI pre dominant
claudication 66%
rest pain 34%
Table 23: Outcome of PTA and bypass offemoropopliteal obstructions-claudication (modified from
Hunink et al45)
PTA-stenosis
PTA- occlusion
Femorop opllrcal bypass-vein
Fcmoro poplireal bypass-PTFE AI<
Fern oropopliteal bypass-PTFE BK
Patmcymodeled on 5years (%)
68
35
80
75
65
B 4.3.5 Femoropopliteal Stents
The most troublesome lesions for femoropopliteal PTA include eccentric stenoses, long-segment
stenoses and occlusions, and stenoses due to intimal hyperplasia at graft anastomoses. Balloon
dilatation of these lesions can fail because of elastic recoil. It also may fail because of obstructing
intimal flaps caused by extensive dissection. Stents have been applied as a potential solution. In
general, the immediate and early results have been excellent, and many cases of angioplasty fail-
ure have been converted to early successes because of the impact of stenrs, However, restenosis
caused by intimal hyperplasia in the stented segment is quite common in the first 3 to 9 months
after treatment. Preliminary studies using a variety of stcnts show less than promising results
because of intimal hyperplasia and occlusion (Table 24) .26,27,46,48 ,49,50,51 There is some refer-
ence to an inc reased risk of compression of balloon-expandable stents in femoropopliteal arter-
Recommendation 36: Femoropopliteal stenting in PAD
Femoropopliteal stenting as a primary approach to the interventional treatment of inter-
mittent claudication or eLI is not indicated. However, stents may have a limited role in
salvage of acute PTA failures or complications.
Sl08 B4 Treatment ofIntermittent Claudication
Figure 23: Average results for endovascular treatment.
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ies. This may be caused by external trauma or muscle compression within the adductors canal.
Therefore, the use of self expandable stents seems advisable. 52
In general, it may be stated that the experience with infrainguinal stenting for femoropopliteal
disease has been limited. Stenrs appear indicated only for salvage of failed PTA attributable to
dissection or marked recoil. Finally, covered stems may have a role in limiting or preventing
restenosis caused by intimal hyperplasia. This concept is in trials now, but has not yet been
proved.
Cejna et al56 performed a multicenter, randomized trial. PTA was compared with Palmaz stent
implantation in femoropopliteal artery obstructions in 142 patients (154 lesions). In 10 of77
patients randomized to balloon angioplasty, primary PTA failed (12.9%) as compared with one
primary stent failure (1.3%). Cumulative primary angiographic patency rates for PTA were 79%,
64%, and 53% at 6, 12, and 24 months, respectively. Primary patency rates for stent placement
were 86%, 63%, and 58% at 6, 12, and 24 months, respectively. Thus, despite better short-term
and midterm results, primary stenting does not improve long-term success rates as compared
with PTA alone. Table 25 summarizes the weighted-average primary patency rates for iliac and
femoropopliteal procedures.
B 4.3.6 Infrapopliteal PTA
Unlike the aortoiliac and femoropopliteal segments, the infrapopliteal vessels are usually not
treated unless there is critical acute or chronic limb ischemia. Therefore, most of the experience
in infrapopliteal endovascular recanalization has come from patients with limb-threatening
ischemia. However, more recent reports of PTA of tibial arteries have also included patients
with severe claudication.57,58,59,60 The primary goal of infrapopliteal PTA in patients with I'C is
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Table 24: Stents in femoropopliteal arteries-stenoses and occlusions
Claud- Technical
Patients Study icants success Primarypatency rate (%)' Complic-
(limbs) design (%) (%) 1y 3y 5y ation (%)f Comments
Rousseau ct al,46 1989 36 (40) P 78 100 76 a f/up based on DSAj
25%lesions>7 ern
length; 30% total
occlusions
Zollikofer et al,47 1991 13 (15) P 76 93 55 18 6.6 f/up based on ABPI
and angiography;
80%occlusions with
avernge length 13.5cm
Do et al,48 1992 26 (26) P 85 100 59 f/up based on ABP1
and duplex; 100%
occlusions; 69% sec-
Sapoval er al,49 1992
ondary patencyat 1 y
21 (22) P 86 95 49 49 4.5 f/up based on
duplex and angiogra-
phy; 82%occlusions;
67%secondary
patency at I y
Liermann er al,50 1992 48 (48) R 65 94 71 4 f/up based on ABPI
Henry er al,26 1995 126 (126) P 93 99 81 72 65 1 F/up based on duplex;
major complications
from both iliac and
femoropopliteal
arteries; 31%occlu-
sions; 96%secondary
patency at 1 y, 1.8% SE
Martin et al,27 1995 96 (96) p 77 61 17 f/up based on ABPI;
84% secondary
White et al,53 1995
patency at 1 y
32(32) P 94 100 75 F/up based on
Doppler; 47% occlu-
sions; 93%secondary
patency at 1 y
Bray et al,54 1995 (57) P NA 100 79 f/up based on
Duplex; 61% occlu-
sions; 82%secondary
Strecker et al,5! 1997
patency at 1 y
80 (80) P 82 98 76 48 8.8 f/up based on ABPI;
59%occlusions
Gray & Olin,55 1997 50(58) p 50 100 22 12.0 f/up based on
Duplex; 89% occlu-
sions with avo length
16.5 cm; 46% secondary
patency at 1 y
Weightcd average 585 (600) 80 98 67 58 7.3
Abbreviations: R, retrospective; P, prospective; !/up, follow-up.
'Including technical failures.
[ Including major or "significant" complications, as far as Call be distinguished from the text.
Critical Issue 15: Infrapopliteal percutaneous transluminal angioplasty in intermittent
claudication
The role of infrapopliteal percutaneous transluminal angioplasty to improve run-off
in intermittent claudication remains to be established.
improvement of the outflow after femoropopliteal PTA, stent placement, or bypass. The ratio-
nale tor this is the fact that the distal runoff has a significant influence on the long-term patency
rates after fernoropopliteal PTA and bypass surgery.37,38,61 Dotter and Judkins! and others first
described infrapopliteal PTA; however, results were mixed,l,62,63 The efficacy of infrapopliteat
PTA has been substantially improved by technical developments, such as DSA with road map-
ping, steerable guidewires, and low-profile balloons. Indications for treatment are categorized
by symptomatology, anatomic localization, and clinical outcome (see also C 4.2, Endovascular
SlID B4 Treatment of Intermittent Claudication
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Table 25: Weighted-average primary patency rate in patients with intermittent claudication, including tech-
nical failures. Patency rates excluding technical failures are shown in parentheses.
Technical Primary patmcy rate (%)
success (%) 1y 3y 5y
PTA iliac stenoses 95 78 (83) 66 (71) 61 (66)
PTA iliac occlusions 83 68 (85) 60 (77)
Stems iliac stenoses 99 90 (91) 74 (75) 72 (73)
Stems iliac occlusions 82 75 (90) 64 (82)
PTA femoropopliteal 90 61 (71) 51 (61) 48 (58)
Stems femoropopliteal 98 67 (69)
Procedures for Acute Limb Ischemia, p S151; D 4.6, Aortoiliac Disease-Endovascular
Treatment, p 5214; D 4.9.2, Infrapopliteal Angioplasty, p 5229). In summary, experience is
accumulating that demonstrates the effectiveness and safety of infrapopliteal artery PTA.
However, it is still debatable whether infrapopliteal PTA should be performed in patients with
IC for improvement of outflow and for an increased patency of proximal dilatation sites.
B 4.3.7 Complications of Bndovascular Procedures
Complications of percutaneous treatments of PAD include the risks of the diagnostic study with
the increased risks of all the therapeutic modalities employed: lysis, PTA, stents. Interventional
morbidity increases because of larger vascular access that often is needed for treatment and the
use of anticoagulation, and also because of the additional catheter-guidewire manipulations
needed for therapy. Published complication rates vary considerably. As with efficacy, reporting of
complications is not standardized. Some series have included complications with no clinical
sequelae or have classified technical failure as a complication.vi Many older reports included as
complications events that currendy could be managed by either percutaneous techniques
applied during the ongoing procedure (eg, lysis for distal embolic events) or noninvasive
maneuvers (eg, ultrasound-guided compression for femoral pseudoaneurysms). Furthermore, it
is difficult to derive a single value for complication rates in c1audicants or CLI patients alone,
because most reported series comprise both claudicators and limb salvage patients.
Complications can be classified as major (resulting in unplanned increase in the level of care,
prolonged hospitalization, permanent adverse sequelae or death) or as minor. Becker et a165
reviewed complications of 4,662 published PTA procedures. Major complications were observed
in 5.6%. In 2.5%, surgery was required; limb loss was observed in 0.2%, and another 0.2% died.
Minor complications were observed in 4.6%. In a prospective series accumulated after the period
covered by Becker's review, Matsi and Manninen66 noted a similar complication rate of 10.5%,
with 2% requiring operative repair. As with Becker et al, these authors noted that major compli-
cations constitute approximately half of the total (major plus minor) complications. When per-
cutaneous or interventional therapy is applied to treat complications associated with PTA, it can
be expected to be successful in 75% of patients.vs The most common complications are throm-
boembolic vessel occlusions and puncture site injury such as a hematoma or false aneurysm.
Table 26: Summary of aggregate complication rates for endovascular procedures
Source
Table 17
Table 18
Bosch & Hunink.If 1997
Bosch & Hunink.lf 1997
Table 21
Table 24
A ortoiliac interventions;
PTA of a stenosis
PTA of an occlusion
PTA all lesions
Stents all lesions
Femoropopliteal interventions;
PTA
Stems
Weighted average complication rate (range)
3.6% (2.3-4.4%)
6% (3.1-10.6%)
4.3%
5.2%
4.3% (2.4-6.3%)
7.3% (0-17%)
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Less commonly, complications occur at the PTA site itself, including thrombosis, dissection, per-
foration, and occlusion. Endovascular Procedures (B 4.3, S97) and Section D 4.12.5, Incidence
and Management of Complications, give aggregate complication rates for specific procedures,
which are also summarized in Table 26.
Gardiner et al67 reviewed the complications of PTA and reported a rate of major complications
of 3% for iliac PTA and 3% for femoropopliteal PTA. Hence, there may be no difference in com-
plication rate between iliac and femoropopliteal PTA. In studies of stcnt placement, higher com-
plication rates were reported, which might be explained by tile learning curve of the investiga-
tors. Martin et al27 noted that femoropopliteal stent placement engendered higher complication
rates than iliac stent placement because of bleeding related to the antegrade approach; the more
frequent use of anticoagulation during and after stent placement in the infrainguinal vessels
(when compared with the iliac arteries) is probably another factor. Recanalization of iliac artery
occlusions has an increased level of complications (mostly thromboembolic events) of 6% to
16%,6,7,8,9,15,26 especially when the occlusions are longer than 2 cm.66
Complex lesions associated with long procedure times and multiple catheter manipulations and
exchanges probably predispose to higher complication rates. Patient factors such as obesity can
increase puncture site complications. Cardiac and renal comorbidities frequently found in this
group also contribute to increased risk. The 30-day mortality rate of patients undergoing PTA
was 4% in one recent study; the claudicators in this group had a 0.5% 30-day mortality rate,
whereas the limb salvage patients endured a 10% 30-day mortality rate.66 Thus, the complexity of
limb salvage patients apparently places them at higher risk than the aggregate population of treat-
ed patients as a whole, but this must be weighed against higher potential surgical morbidity.
Management strategies specific for PTA and stent placement that may reduce the incidence of
potential complications include the use of low-profile devices as well as use of the contralateral
approach in obese patients or in easily accessible lesions.68 Familiarity with ultrasound compres-
sion for puncture-site pseudoaneurysms, lysis for distal embolization, and stent placement for
occluding dissections will all increase effectiveness and decrease morbidity from these procedures.
References
1. Dotter CT, Judkins, MP. Transluminal treatment of arteriosclerotic obstructions: description of a new technic and a preliminary
report ofits application. Circulation 1964;30:654-670.
2. WorkingParty on Thrombolysis in the Management of Limb Ischemia. Thrombolysis in the management of lowerlimbperipheral
arterial occlusion: a consensusdocument. Am J CardioI1998;81:207-218.
3. Tegtmeyer CJ, Hartwell GD, Selby JB, Robertson R, Kron Il., Tribble CG. Results and complications of angioplasty in aortoiliac
disease. Circulation 1991;83(Suppl 1):1-53-1-60.
4. Jeans WD, Amstrong S, Cole SEA, Horrocks M, Baird RN, er al, Fate of patients undergoingtranslurninal angioplasty for lower-
limb ischemia. Radiology 1990;177:559-564.
5. Jorgensen B, Skovgaard N, Norgard J, Karle A, Holstein P. Percutaneous translurninal angioplasty in 226 iliac artery stenoses: role
of the superficial femoral artery for clinical success. Vasa 1992;21:382-386.
6. Johnston KW: Iliacarteries: reanalysis of results of balloonangioplasty, Radiology 1993;186:207-212.
7. Colapinto RF, Stronell RD, Johnston WK. Transluminal angioplasty of completeiliac obstructions. AJR1985;146: 859-862.
8. Hauscgger KA, LamrnerJ, Klein GE, Fluckiger F, Lafer M, PilgerE, et al. Percuta.neous recanalization of pelvic artery occlusions:
fibrinolysis, PTA,stents. ROFO 1991;155:550-555.
9. BlumU, GabelmannA, Redecker M, NiildgeG, Dornberg W,GrosserG, er al. Percutanous recanalization ofiliac arteryocclusions:
results of a prospective study, Radiology 1993;189:536-540.
10. Gupta AI<, Ravimandalam K, Rao VR, Joseph S, Unni M, RaoAS, et al. Total occlusion of iliac arteries: results of balloon angie-
plasty. Cardiovasc Intervent R.~dioI1993;16:165-177.
11. Rutherford RB, Durham J. Percutaneous ballon angioplasry for arteriosclerosis obliterans: long term results. In: Yao JST, Pearce
WH, eds, Techniques in Vascular Surgery. Philadelphia: Saunders, 1992:329-345.
12. BeckerGJ, Katzen BT, Dake MD. Noncoronary angioplasty. Radiology 1989;170:921-940.
13. Tegtmeyer CJ, Harwell GD, Selby JB, Robertson R Ir, Kron IL,Tribble CG. Results and complications of angioplasty in aortoiliac
disease. Circulation 1991;83(suppl1):1-53-1-60.
14. Johnston J0N. Iliacarteries: reanalysis of results of balloon angioplasty. Radiology 1993;186:207-212.
15. VorwerkD, GUnther RW, Schurmann K, Wendt G, Peters1. Primary stent placement for chronic iliac artery occlusions: follow-up
results in 103 patients. Radiology 1995;194:745-749.
8112 B4 Treatment of Intermittent Claudication
JOUR.,."lAL OF VASCULARSURGERY
January 2000
16. Bonn J. Percutaneous vascular intervention: value of hemodynamic measurements. Radiology 1996;201:18 -20.
17. Tetteroo E, Haaring C, van del' Graf Y, van Schalk JP. Van Engelen AD, Mali WP. Intraarterial pressure gradients after randomized
angioplasry and stenting of iliac artery lesions. Dutch Iliac Stent Trial Group. Cardiovasc Intervent RadioI1996;19:411-417.
18. Bosch IL, Hunink MGM. Metaanalysis of the results ofpereutaneous transluminal angioplasry and stenr placement for aortoiliac
occlusive disease. Radiology 1997;204:87-96.
19. Laborde JC, Palmaz JC, Rivera FJ, Encarnacion CE, Picot MC, Dougherty SP. Influence of anatomic distribution of atherosclero-
sis on the outcome of revascularization with iliac srent placement. J Vase Intervent Radio! 1995;6:513-521.
20. Brewster DC. Clinical and anatomical considerations for surgery in aortoiliac disease and results of surgical treatment. Circulation
1991;83(SuppII):142-152.
21. Tetteroo E, van del' GraafY, Bosch JL, van Engelen AD, Hunink MG, Eikelboom BC, et al. Randornised comparison of primary
stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. Dutch
Iliac Stent Trial Study Group. Lancet 1998 Apr 18;351(9110):1153-1159.
22. Palmaz JC, Laborde JC, Rivera FJ, Encarnacion CE, Lutz JD, Moss JG. Srenting of iliac arteries with the Palrnaz stent: experience
from a multicentric trial. Cardiovasc Intervent RadioI1992;15:291-297.
23. Strecker EP, Hagen P, Liermann D, Schneider B, WolfHR, Wambsganss J, er al. Iliac and fernoropoplitcal vascular occlusive disease
treated with flexible tantalum stents, Cardiovasc Intervent Radiol 1993;16:158-164.
24. WolfYG, Schatz RA, Knowles HJ, Saeed M, Bernstein EF, Dilley RE. Initial experience with the Palmaz srcnr for aortoiliac stenoses.
Ann Vasc Surg 1993;7:254-261.
25. Long AL, Sapoval MR, Beyssen EM, Auguste MC, Le Bras Y, Raynaud AC, et al. Strecker stent implantation in iliac arteries: paten-
cy and predictive factors for long-term success. Radiology 1995;194:739-744.
26. Henry M, Arnor M, Ethevenot G, Henry I, Arnicabile C, Beron R, et al. Palrnaz srenr placement in iliac and fernoropopliteal arter-
ies: primary and secondary patency in 310 patients with 2-4 year follow-up. Radiology 1995;197:167-174.
27. Martin EC, Katzen BT, Benenati JF, Diethrich EB, Dorms G, Graor RA, et al, Multicenter trial of the Wallstent in iliac and femoral
arteries. }VIR 1995;6: 843-849.
28. Vorwerk D, Gunther RW, Schurrnann K, Wendt G. Aortic and iliac stenoses: follow-up results of stent placement after insufficient
balloon angioplasry in 118 cases. Radiology 1996;198:45-48.
29. Murphy TP, Webb MS, Lambiase RE, Haas RA, Dorfman GS, Csarney WI, er al. Percutaneous revascularization of complex iliac
artery stenoses and occlusions with use of Wallstent: three-year experience. }VIR 1996;7:21-27.
30. Smith GD, Shipley MJ, Rose G. Intermittent claudication, heart disease risk factors, and mortality: The Whitehall Study, Circulation
1990;82:1925-1931.
31. Criqui MH, Langer RD, Fronek A, Feigelson HS, K1aubcr MR, McCann TJ, et al. Mortality over a period of 10 years in patients
with peripheral arterial disease. N Engl J Med 1992;326:381-386.
32. Criqui MH, Fronek A, Klauber MR, Barrett-Conner E, Gabriel S. The sensitivity, specificity, and predictive value of traditional clin-
ical evaluation of peripheral arterial disease: results from non-invasive testing in a defined population. Circulation 1985;71:516-522.
33. Vogt MT; Cauley JA, Newman AB, Kuller LH, Hulley SB. Decreased ankle/arm blood pressure index and mortality in elderly
women. JAMA 1993;270:465-469.
34. Newman AB, Sutton-Tyrrell K,Vogr MT, Kuller LH. Morbidity and mortality in hypertensive adults with a low ankle/arm blood
pressure index. JAMA 1993;270:487-489.
35. Applegate WE. Ankle/arm blood pressure index: a useful test for clinical practice] JAMA 1993;270:497-498.
36. Newman AB, Siscovick DS, Manolio TA, Polak J, Pried LP, Borhani NO, et al, Ankle/arm index as a marker of atherosclerosis in
the cardiovascular health study. Circulation 1993;88:837-845.
37. Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty, factors influencing long-term success. Circulation 1991;83: 1-
70-1-80.
38. Johnston KW. Femoral and poplital arteries: reanalysis of results of balloon angioplasty. Radiology 1992;18 3:767-771.
39. Matsi PJ, Manninen HI, Vanninen RL, Suhonen MT, Oksala I, Laakso M, et al, Femoropopliteal angioplasty in patients with clau-
dication: primary and secondary patency in 140 limbs with 1-3 year follow-up. Radiology 1994;191:727-733.
40. Murray JG, Apthorp LA, Wilkins RA. Long-segment (>10 ern) fcrnoropoplircal angioplasty: improved technical success and long-
term patency. Radiology 1995;195:158-162.
41. Gallino A, Mahler F, Probst P, Nachbur B. Percutaneous transluminal angioplasty of the arteries of the lower limbs: a 5 year follow-
up. Circulation 1984;70(4):619-623.
42. Krepel VM, van Andel GJ, van Erp WF, Breslau PJ. Percutaneous trans luminal angioplasty of the femoropopliteal artery: initial and
long term results. Radiology 1985;156(2):325-328.
43. Hunink MG, Donaldson MC, Meyerovitz MF, Polak JF, Whittemore AD, Kandarpa K, et al. Risks and benefits of fernoropopliteal
percutaneous balloon angioplasty, J Vasc Surg 1993;17(1):183-192.
44. Currie IC, Wakeley C}, Cole SE, Wyatt MG, Scott DJ, Baird RN, et al, Femoropoplitcal angioplasty for severe limb ischemia, Br J
Surg 1994;81:191-193.
45. Hunink MGM, Wong JB, Donaldson MC, Meyerovitz MF, de Vries J, Harrington DP. Revascularization for femoropopliteal dis-
ease: a decision and cost-effectiveness analysis. JAMA 1995;274:165-171.
46. Rousseau HP, Raillat CR, Joffre FG, Knight CJ, Ginestet MC, et al, Treatment of'fernoropopliteal stenoses by means of self-expand-
able endoprostheses: midterm results. Radiology 1989;172:961-964.
47. Zollikofer CL, Antonucci P, Pfyffer M, Redha F, Salomonowitz E, Sruckrnann G, et al. Arterial stent placement with use of the
Wallstent: midterm results of clinical experience. Radiology 1991;179:449-456.
48. Do-del-Do, Triller J, Walpoth BH, Stirnemann P, Mahler F. A comparison study of self-expandable srents vs balloon angioplasty
alone in femoropoplitcal artery occlusions. Cardiovasc Intervent Radiol 1992;15:306-312.
JOURNAL OF VASCULAR SURGERY
Volume 31, Number 1, Part 2 B4 Treatment of Intermittent Claudication 8113
49. Sapoval MR, Long AL, Raynaud AC, Beysson BM, Plessinger IN, Gauz JC, et al. Femoropopliteal stent placement: long-term
results. Radiology 1992;184:8334-839.
50. Liermann D, Strecker EP, Peters J. The Strecker stent: indications and results in iliac and fernoropopliteal arteries. Cardiovasc
Intervent RadioI1992;15:298-305.
51. Strecker EP, Boos IB, Gottmann D. Fcmoropopliteal artery stent placement: evaluation of long-term success. Radiology
1997;205(2):375-383.
52. Rosenfield K, Schainfeld R, Pieczek A, Haley L, Isner JM. Restenosis of endovascular stents from stent compression. J Am Coli
Cardiol 1997;29:328-338.
53. White GH, Liew SC, Waugh RC, Stephen MS, Harris JP, Kldd ], et al,Early outcome and intermediate follow-up ofvascularstcnts
in the femoral and popliteal arteries without long-term anticoagulation. J VaseSurg 1995;21(2):270-279.
54. Bray AE, Liu WG, Lewis WA, Harrison C, Maullin A. Strecker stenrs in the femoropopliteal arteries: value of duplex ultrasonogra-
phy in restenosis assessment. J Endovasc Surg 1995;2(2):150-160.
55. Gray BH, Olin JW. Limitations of percutaneous transluminal angioplasty with stenting for femoropopliteal arterial occlusivedisease.
Sernin Vase Surg 1997;10(1 ):8-16.
56. Cejna M, Illiasch H, Walden berg P, Horvath W, Thurnber SA, Lammer J. PTA vs Palmaz stent in femoropopliteal obstructions: a
prospective randomised trial-long term results. Radiology 1998;209:492.
57. Horvath W, Oerrl M, Haidinger D. Percutanoues translurninal angioplasty of crural arteries. Radiology 1990;177: 565-569.
58. Flueckiger F, Lamrner ], Klein GE, Hausegger K, Pilger E, Waltner F, et al. Percutanous transluminal angioplastyof crural arteries.
Acta Radiol 1992;3:152-155.
59. Bull PG, Mendel H, Hold M, Schiegl A, Denck H, et al, Distal popliteal and tibioperoneal transluminal angioplasty: long-term tal-
low up. ]VIR 1992;3:45-53.
60. Wagner HJ, Starck EE, McDermott JC. Infrapopliteal percutanous transluminal revascularization: results of a prospective study on
148 patients. J Intervent R.1diol1993;8:81-90.
61. Pilger E, Lammer J, Berruch H, Stark G, Decrinis M, Pfeiffer KP, et al. ND:YAG laser with sapphire tip combined with balloon
angioplasty in peripheral arterial occlusions: long term results. Circulation 1991 ;83: 141-147.
62. Starck EE, McDermott J, Crummy AB, et aI. Angioplasty of the popliteal and tibial arteries. Sernin Intervcnr RadioI1984;4:269-
277.
63. Tamura S, Sniderman KW, Beinart C, Sos TA. Percutaneous transluminal angioplasry of the popliteal arteries and its branches.
Radiology 1982;143:645-648.
64. Ballard JL, Sparks SR, Talor FC, Bergan J], Smith DC, Bunt T], et al. Complicatoins of iliac artery stent deployment. J Vase Surg
1996;24:545-555.
65. Becker GJ, Katzen BT, Dake MD. Noncoronary angioplasty, Radiology 1989;170:921-940.
66. Matsi PJ, Manninen HI. Complications of lower-limb percutaneous transluminal angioplasty: a prospective analysis of 410 proce-
dures on 295 consecutive patients. Cardiovasc Int RadioI1998;21:361-366.
67. Gardiner GA Ir, Meyerovitz MF, Stokes KR, Clouse ME, Harrington DP, Betrmann MA. Complications of transluminal angioplas-
ty. Radiology 1986;159:201-208.
68. Kashdan BJ, Trost DW, [agust MB, Rackson ME, Sos TA, et aI. Retrograde approach for contralateral iliac and infrainguinal per-
cutaneous transluminal angioplasry: experience ill 100 patients.]VIR 1992;3:515-521.
B 4.4 Surgery for Intermittent Claudication
B 4.4.1 Introduction
The most compelling indication for an open surgical revascularization procedure on the lower limb
is critical limb ischemia (rest pain, tissue loss). Therefore, surgical procedures are discussed in
greater breadth and depth in the section of the document dealing with CLI (Section D4,
Treatment of Critical Limb Ischemia, p S192). The following section addresses only the limited
application of surgical procedures appropriate to the treatment of patients with IC.
Surgery is rarely necessary in patients with IC; in fact, surgery should be avoided initially and other
options pursued in most patients. The generalized disease process present in patients with athero-
sclerotic occlusive disease is not benefited by limb revascularization, other than the relatively minor
considerations that increasing exercise capacity may improve conditioning and allow exercise thera-
py for angina. The overriding consideration is that, in the claudicant, the threat to life of general-
ized atherosclerosis takes priority over the limited threat to limb of the peripheral lesions. In a
non-limb-threatening situation, conservative treatment will provide sufficient improvement in
most, so the risk of both early and late complications associated with bypass grafting cannot be jus-
